8 h. ago Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development

BEIJING — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a global licensing agreement with BeOne Medicines Ltd., a global oncology company, for multiple fully human antibodies. Prior to this licensing […]

Sport

7 d. ago Synedgen Promotes Dr. Laura Saward to Chief Executive Officer and Appoints Dr. Kenton Gregory to Chief Medical Officer

– As Synedgen’s Chief Executive Officer and Chief Scientific Officer, Dr. Saward will continue to lead the company to deliver on the successful partnership with Biomedical Advanced Research Agency (BARDA) and leverage her significant expertise in drug development and licensure – – Dr. Gregory has been appointed Chief Medical Officer bringing a wealth of experience […]

Events

9 d. ago Algernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling $621,000

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is announcing amended pricing and warrant terms for its non-brokered […]

Economics

9 d. ago Portal Biotech Raises $35 Million Series A, Leveraging AI to Deliver the World’s First Full

Breakthrough proteomics platform technology unlocks full-length protein sequencing and characterisation, accelerating drug development and diagnostics LONDON, June 30, 2025 (GLOBE NEWSWIRE) — Portal Biotech, a pioneering biotechnology company headquartered in London, today announced a $35 million Series A raise, representing one of Europe’s largest investments into a life sciences tools company. This significant milestone positions […]

Economics

2 w. ago Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results

LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing   Five U.S. government proposals submitted, totalling up to US$125 million HALIFAX, Nova Scotia, June 25, 2025 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today […]

Other

2 w. ago Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML

SAN DIEGO and TORONTO, June 20, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that it has entered into a new loan agreement […]

Economics

3 w. ago  ZYUS Life Sciences Announces Closing of First Tranche of Unit Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SASKATOON, Saskatchewan — ZYUS Life Sciences Corporation (the “Company”) (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that it has now completed […]

Other